Equity Profile

BIO

Bio-Rad Laboratories, Inc.

Health CareLife Sciences Tools & Services$7.9B

Jul30Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and meet demand in the life sciences sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services. Their products are essential for research and clinical diagnostics, making them significant players in the ongoing advancements in health care and biotechnology.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

In Q1-2026, Bio-Rad reported an EPS of $1.89, which was significantly below the expected $2.77, resulting in a 31.77% surprise. Following the report, the stock saw a modest increase of 1.81% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Bio-Rad's upcoming earnings are mixed, especially after a disappointing Q1. Investors will be closely watching for signs of recovery in both EPS and revenue.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improved EPS, it may signal a rebound in demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its market position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Bio-Rad provide for its life sciences tools segment?

This will help investors understand the demand trends and market position of Bio-Rad in a competitive landscape.

Will management address the factors that led to the significant EPS miss in Q1-2026?

Clarification on this issue could either reassure investors or raise further concerns about the company's operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's potential for recovery, as recent investments in R&D could lead to new product launches that drive growth.

Supporting Evidence

The options market is pricing a 17.11% move, indicating higher volatility than usual, which could reflect underlying investor uncertainty.

Bio-Rad's historical performance shows a mixed reaction to earnings, suggesting that the market may be overly pessimistic about its recovery potential.

Key Risk

If Bio-Rad can demonstrate a strong rebound in revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Bio-Rad can recover from its recent earnings miss and demonstrate growth in a competitive market.

Bull Confirmed If

A revenue growth rate of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS below $1.50 would indicate ongoing challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could react positively, potentially increasing by around 1.67%. This would confirm a recovery narrative.

In-Line / Cautious

If results are in line but management is cautious, the stock may remain flat or see a small decline as investors digest the commentary.

Miss

If Bio-Rad misses expectations again, history suggests a decline of around 0.97%, which could raise serious concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the life sciences segment.
2Management's commentary on market demand and competitive positioning.
3Insights into cost management strategies and operational efficiency.
4Details on any changes in customer contracts or partnerships.
5Guidance on expected performance for the upcoming quarters.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jul27

KRCAMC

Kilroy Realty Corporation

PreviewView

Jul27

PIIAMC

Company Snapshot

Bio-Rad Laboratories, Inc. is a leading company in the health care sector, specializing in life sciences tools and services....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a crucial indicator of the company's profitability and will help investors gauge financial health this quarter.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and meet demand in the life sciences sector.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

BIO Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

+15.34%

Avg Stock Reaction

-1.01%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall expectations for Bio-Rad's upcoming earnings are mixed, especially after a disappointing Q1. Investors will be closely watching for signs of recovery in both EPS and revenue.

Bull Case

If Bio-Rad can demonstrate strong revenue growth and improved EPS, it may signal a rebound in demand for its products, boosting investor confidence.

Bear Case

Conversely, if the company fails to meet expectations again, it could raise concerns about its market position and future growth prospects.

Expectations

Two Questions That Matter

The print will turn on these two things.

What specific revenue growth figures can Bio-Rad provide for its life sciences tools segment?

This will help investors understand the demand trends and market position of Bio-Rad in a competitive landscape.

Will management address the factors that led to the significant EPS miss in Q1-2026?

Clarification on this issue could either reassure investors or raise further concerns about the company's operational efficiency.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating Bio-Rad's potential for recovery, as recent investments in R&D could lead to new product launches that drive growth.

Supporting Evidence

The options market is pricing a 17.11% move, indicating higher volatility than usual, which could reflect underlying investor uncertainty.

Bio-Rad's historical performance shows a mixed reaction to earnings, suggesting that the market may be overly pessimistic about its recovery potential.

Key Risk

If Bio-Rad can demonstrate a strong rebound in revenue growth, it could challenge the current bearish sentiment.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Bio-Rad can recover from its recent earnings miss and demonstrate growth in a competitive market.

Bull Confirmed If

A revenue growth rate of over 10% year-over-year would confirm the bull case.

Bear Confirmed If

An EPS below $1.50 would indicate ongoing challenges and confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±17.11%

Historical Avg

±1.7%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±17.1% while BIO has averaged ±1.7% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.4%

30d HV

58.0%

Calls (2K)P/C Ratio: 0.33Puts (400)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Bio-Rad beats expectations, history suggests the stock could react positively, potentially increasing by around 1.67%. This would confirm a recovery narrative.

In-Line / Cautious

If results are in line but management is cautious, the stock may remain flat or see a small decline as investors digest the commentary.

Miss

If Bio-Rad misses expectations again, history suggests a decline of around 0.97%, which could raise serious concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product launches in the life sciences segment.
2Management's commentary on market demand and competitive positioning.
3Insights into cost management strategies and operational efficiency.
4Details on any changes in customer contracts or partnerships.
5Guidance on expected performance for the upcoming quarters.